Moderna Free Cash Flow (FCF) History (MRNA)

Moderna reported −$2.06B in free cash flow for fiscal 2025, an increase of $1.99B from the previous fiscal year, with a free cash flow margin of −106.22%.

View full Moderna company overview

Moderna free cash flow by year

Moderna annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$2.06B$1.99B−106.22%
20242024-12-31−$4.05B−$230.0M−125.31%
20232023-12-31−$3.83B−$8.41B−55.86%
20222022-12-31$4.58B−$8.76B−65.65%+23.78%
20212021-12-31$13.34B$11.38B+580.76%+72.20%
20202020-12-31$1.96B$2.45B+243.96%
20192019-12-31−$491.0M−$54.4M−815.49%
20182018-12-31−$436.6M−$46.7M−323.27%
20172017-12-31−$389.9M−$423.5M−189.43%
20162016-12-31$33.6M+30.99%

Moderna free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from $1.96B to −$2.06B, a net decrease of $4.02B. Moderna's latest reported quarter, Q2 2026, generated −$563.0M in free cash flow, an increase of $359.0M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Moderna filings at SEC.gov ↗